Descriptions are
generated automatically from the ICTVdB database including links. Some
descriptions are only very basic and links may point to documents that are not
yet published on the Web.
00.073.0.01.026. Venezuelan
equine encephalitis
Cite this publication as: ICTVdB
Management (2006). 00.073.0.01.026. Venezuelan equine encephalitis. In:
ICTVdB - The Universal Virus Database, version 4. Büchen-Osmond, C.
(Ed), Columbia University, New York, USA
Cite this site as: ICTVdB -
The Universal Virus Database, version 4.
http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/
Isolation date: 03 March 1938.
Location: Caracas; Venezuela; the United States of America.
Host of Isolate and Habitat Details
Source of
isolate: guinea pigs, mice, chicken embryo.
Virus was isolated from an adolescent.
Collection and Isolation Details
Virus was
isolated by Beck, Wyckoff. The United States of America.
Reference to Isolation Report
Beck, Wyckoff (1938), Science 88, 530.
Biocontainment Level
Distribution of this virus
falls under quarantine restrictions. It is recommended to handle this virus at
the biocontainment level BSL-3.
This is a description of an
invertebrate or vertebrate virus at the species
level with data on all virus properties from morphology to genome,
replication, antigenicity and biological properties.
ICTVdB Virus Code: 00.073.0.01.026. Virus accession number:
73001026. Obsolete virus code: 73.0.1.0.026; superceded accession number:
73010026.
NCBI Taxon Identifier NCBI Taxonomy ID:
11036.
Name, Synonyms and Lineage
The taxon has the
accepted ICTV name.
ICTV approved acronym: (VEEV). Virus is an ICTV approved species. Virus is of
the genus 00.073.0.01.
Alphavirus in the family
00.073.
Togaviridae; not assigned to an order.
Symptoms in the host are
well established and the causative agent is determined.
Distinct viral structures are visible in thin sections of infected tissue
and nucleic acid of virions is encapsidated. Size and shape of virus has
been determined by electron microscopy.
Virions consist of an envelope, spikes, and a
nucleocapsid. During their life cycle, virions have not been observed outside a
cellular environment and have a cell-associated cycle and occur
in one phenotype
only. Virus capsid is surrounded by a single layer envelope and virions
mature naturally by budding through the membrane of the host
cell. Virions are spherical and measure
60-65 nm in diameter. The
envelope surrounds one nucleocapsid. Envelope has surface projections. Surface
projections are distinctive, knob-shaped spikes that are evenly dispersed
covering the entire surface and are
embedded in a lipid bilayer which is comprises hemagglutinin. Surface projections are
composed of different types of glycosylated proteins which determin the anigenecity.
The projections are formed by proteins designated E1 and E2,
which exhibit hemagglutinin activity. Host ribosomes are not
seen inside the envelope. A regular capsid structure is present.
Capsid/nucleocapsid is round and exhibits icosahedral symmetry
(T=4). The nucleocapsid is isometric
and has a diameter of 40 nm. The capsid shells of virions are
composed of a single layer. Capsids appear round. Nucleocapsid contains a
nucleoprotein complex.
Virion populations are comprised of particles of uniform size. Capsids all
have the same appearance and only one species is recovered in
preparations.
The molecular mass (Mr) of virions is 52 x 106.
Virions have a buoyant density in sucrose of 1.22 g cm-3. The
sedimentation coefficient is 280 S20w. Virion infectivity is
inactivated and destroyed by heating for 10 min above
56°C. Extent of effect on virion infectivity is reduced by heat. Under
in vitro conditions virions are stable when stored at -70°C;
relatively stable when stored at -40°C, not stable at
-20°C or above, or 37°C (half-life about 7 hours). Virions are inactivated
in acid environment of pH 1-3, but are stable in alkaline
environment of pH 7-9. Virions are sensitive to treatment with lipid
solvents, detergents, ether, trypsin, chloroform, formaldehyde, heat, and
ß-propiolactone. The infectivity is reduced after exposure to irradiation.
The
genome is monomeric; not segmented and contains a single molecule of
linear, positive-sense, single-stranded RNA.
The genome is infectious. Minor species of genomic nucleic acid are not found.
The complete genome is 11444 nucleotides long. Sequence can be accessed from
GenBank. The RNA is fully sequenced, complete sequence is 11444
nucleotides long and encodes 6K, C, E1, E2, E3, nsP1, nsP2, nsP3
and nsP4. NCBI reference genome has the accession number
[NC_001449]. Nucleotide sequences at the 3'-terminus are identical
and unrelated to the 5'-terminus. The 3'-terminus has no long
non-coding region; conserved nucleotide sequences; of 19 nucleotides in length;
in species of same genus. The 3'-terminus has a poly (A) tract. Each virion
contains a single copy of the genome; a full length copy.
Reference to nucleotide sequence in PubMed:
nucleotide sequences;
complete genome sequences.
Proteins
have been characterized and functions are assigned to them. Particles are made
up of 3 proteins.
The viral genome encodes structural proteins and non-structural proteins.
Virions consist of 5 structural protein(s) located in the envelope
(E1, E2, E3), nucleocapsid (C) (6k). The viral envelope contains 3 integral
membrane proteins.
Structural Proteins: Envelope protein E1. Envelope protein has
been sequenced and a function assigned. E1 is 442 amino acids long and is
postulated to serve as a fusion protein which possess(es) entry functions into
the cell. Envelope protein E2 has been sequenced and a function assigned. E2
is 423 amino acids long, is a transmembrane protein. During post-translational
processing envelope protein modifications occur that include glycosylation.
Envelope protein E3; has been sequenced and a function assigned. E3 is 59
amino acids long, is an attachment protein. Nucleocapsid protein C
has a molecular mass of 30000 Da; is the product of the polyprotein encoded on
the 3' end of the genome by the S-ORF, as are the other structural proteins; has
been sequenced and a function assigned (C is 275 amino acids long).
Non-Structural Proteins: Virus-coded non-structural
proteins have been identified by sequence analysis and 4
non-structural protein(s) are found (nsP1, nsP2, nsP3, nsP4). The virus codes
for enzymes and replication-associated proteins; an RNA-dependent RNA
polymerase. In addition to the polymerase, the virus codes for enzymes such as
helicase, protease, replicase, and synthetase. The non-structural proteins are
thought to be involved in capping of viral RNAs, initiation of negative strand
RNA synthesis, processing of non-structural proteins, in RNA replication, the
formation of a replicase complex for the minus strand synthesis, and the
synthesis of the plus strand; function in the cytoplasm of infected cells;
polymerase nsP4. Virus coded polymerase has a molecular mass of 19 kDa.
Polymerase has been sequenced. The sequence has the accession number
[P89949]. Non-structural protein
polyprotein 1 has been sequenced and a function assigned. The protein
is coded from NS-ORF; a replication-associated protein that is capping of viral RNAs
and initiating negative strand RNA synthesis) and possesses
methyltransferase activity. Non-structural protein nsP2 has been
sequenced and a function assigned. The protein is coded from NS-ORF. The protein
is a replication-associated protein (functions as a protease to process the
nonstructural proteins, and as a helicase for RNA replication). Non-structural
protein nsP3. Non-structural protein has been sequenced and a function
assigned; the protein is coded from NS-ORF. Non-structural protein nsP4; has
been sequenced and a function assigned.
Lipids are
present in significant amounts and are located in the
envelope. Virions are composed of 30% lipids by weight. The lipids are of host
origin and composition depends on the cell in which the virus replicates.
Lipids are derived from host cell membranes. Viral membranes include
phosphatidyl ethanolamine, phosphatidyl choline, phosphatidyl serine,
cholesterol, and sphingomyelin. Lipids are essential for infectivity.
Carbohydrates are glycoproteins and N-linked
glycans that contain mannose. Carbohydrate composition in the
virion is virus-dependent.
Genome map:
NC_001449.
Genome Organization and Replication
Virions attach to receptors located on the surface of cell membrane,
enter host cells by fusion with, or endocytosis of the
viral envelope.
The process of intracellular uncoating of virions is understood. Virus
uncoating occurs in the cytoplasm; the viral nucleocapsid is delivered
to the cell cytoplasm.
By itself, genomic nucleic acid is infectious.
Infection and Replication: Virus
replication is initiated by the insect host; occurs in the midgut or proceeds to
salivary glands. In the vertebrate host virus replication occurs in
various organs. Replication is not restricted to a particular tissue or organ of
the host. Although severity of illness depends on route and dose, the majority
of infections are subclinical, or mild. Infection involves a noncytocidal
productive infectious cycle (in the invertebrate host), or does not involve a
noncytocidal productive infectious cycle (in the mammalian host). Infected cells
continue to grow slowly (in cells from arthropods), or do not continue to grow
(in cells from vertebrates).
Transcription: The 5' ends of mRNAs
are capped. The 3' ends of mRNAs possess a poly (A) tract.
Translation: The genome replicates in
the cytoplasm.
The virus is serologically
related to all viruses in the genus Alphavirus. Antigenic determinants may be
found on envelopes, spikes, and nucleocapsids and correspond to
each of the major structural proteins, structural glycoproteins, and
non-structural proteins; correspond to each of the major virion proteins C, E1,
E2, E3, nsP1, nsP2, nsP3, nsP4. The type-specific antigenic determinants are
involved in antibody mediated neutralization and hemagglutination inhibition.
Antigenic determinants that possess serogroup-specific reactivity are found on
the nucleocapsids. The serogroup-specific antigenic determinants are involved in
antibody mediated neutralization, hemagglutination inhibition, and complement
fixation. Antigenic specificity of the virion can be determined by
neutralization tests, or hemagglutination inhibition tests, or complement
fixation tests, or ELISA tests, or immunofluorescence assays. In gel-diffusion
tests antisera display cross-reactivities among different members of the taxon.
Serological relationships between different members are very close (but
relationships depends on antigenic complex membership). Cross-reactivity is
found. Cross-reactivity between isolates of the same species and species, but
not genera. Protective immunity is induced in the form of neutralizing
antibodies. Virions are usually satisfactorily stabilized for use as antigens or
immunogens by fixation with glutaraldehyde (or any of many other fixatives). The
virus is immunogenic. The virus serves as an efficient immunogen when
animals are infected with whole virus particle preparations, or disrupted virus
particle preparations, or denatured virus particle preparations. These
preparations produce antibodies. The virus induces antibodies with distinct
reactivities to the subtype-specific determinants, or type-specific
determinants, or serogroup-specific determinants, or complex-specific
determinants, or genus-specific determinants. The virus induces the formation of
neutralizing antibodies, or hemagglutination inhibiting antibodies, or
complement-fixing antibodies. Antibody response that is protective against
infection is usually directed against virion glycoproteins, or virion surface
proteins. The serotype is defined by E proteins. The virus serotype is
determined by a serum neutralization test; using polyclonal antibodies.
Antigenic distances between individual species, expressed as serological
indices, are correlated with the degree of sequence difference in their coat
protein (E1 and E2). Species that are serologically interrelated have antigenic
homologies with different isolates of the same virus species. Although the
degree of antigenic specificity varies with the degree of relatedness, the
antigenicity is considerable between isolates of the same virus
species and species of the same serogroup. Some species in the genus
are related antigenically. They are sharing some epitopes in the structural
proteins (40% homology), or in the non-structural proteins (60% homology). The
virus is closely related to other viruses of the EEV complex and
related to all other alphaviruses. Classification of members of this taxon is
based on their sequence homologies. Minor biological differences have been
recognized between EEE virus isolates. Known sequence homologies with other
viruses. Sequence homologies phylogenetic analyses using nonstructural protein
amino acid sequences indicate that alphaviruses evolved from a common ancestor
which existed a few thousand years ago. Reliable virus detection and
identification can be achieved by serological tests, or PCR techniques, or using
specific primers.
Diagnostics and Reference Collections
The
best tests for diagnosis are PCR, neutralization, IgM, IgG, Elisa, Hi, CF, IFA.
Antisera are commercially available from American Type Culture Collection, or
W.H.O. regional reference centers.
Vaccines are restricted for use in humans.
Vaccines
Vaccines are commercially
available but not licensed for use in humans. Vaccines are not licensed for
experimental use in humans.
Natural Host
Virus infects during its life cycle arthropod and vertebrate hosts. Virus has an
enzootic cycle and is transmitted from arthropod vector to competent reservoir
host, or arthropod vector to an incidental incompetent host (dead end host).
Domain
Viral hosts belong to the Domain Eucarya.
Domain Eucarya
Kingdom Animalia.
Kingdom Animalia
Phylum Arthropoda and
Chordata.
Phylum Arthropoda
Subphylum Hexapoda; Class
Insecta; Subclass Pterygota (winged insects), Order Diptera.
Phylum Vertebrata
Subphylum Vertebrata; Class Mammalia.
Class Mammalia
Order Perissodactyla, Rodentia,
and Primates;
Family Hominidae.
Virus infects Homo sapiens
(human,
Family Equidae: virus infects Equus caballus
(horse).
General Symptoms in Animals Infection can
affect the nervous system, or musculo-skeletal system, or dermis, mucosa or
epithelium. General symptoms include headache, or malaise, or photophobia, or
prostration, or pyrexia, or retardation, or stiff neck, or tremor, or
uncoordination. Lesions are found in nerve tissue. Signs and symptoms include
meningitis, paralysis, sequelae, seizures, encephalitis.
Severity and Occurrence of
Disease
Host: Infection is in mosquito (Culex spp.,
Psorophora spp., Aedes spp). Prevalence of viral infection is
seasonally dependent, and incidences of virus infection are usually observed in
summer and after heavy rainfalls (which are followed by an
increased mosquito population). The incubation period lasts usually a lifetime.
The mosquitoes remain persistently infected and contagious.
Host 2: Any kind of small rodents. The infection is clinically
expressed. Infection is apparent. Signs and symptoms may vary, but are usually
severe. Prevalence of viral infection is seasonally dependent, and incidences
are usually observed in summer.
Host 3: Horses (Equus caballus). Infection is apparent.
The infection is clinically expressed. Although disease expression is dependent
on dose, infection is usually acute. Signs and symptoms may vary, but are
usually severe. Prevalence of viral infection is seasonally dependent, and
incidences are usually observed after heavy rainfalls (which
are followed by an increased mosquito population). Contagiousness is variable;
the incubation period lasts usually 5 day(s). In naturally infected hosts
morbidity rate may be as high as 40 % (case fatality rate in horses).
Host 4: Under natural conditions virus infects Humans (Homo
sapiens). Infection is apparent (, but human infections are unusual.
Children are more susceptible to infection). The infection is clinically
expressed. Although disease expression is dependent on dose, infection is
usually acute. Signs and symptoms may vary, but are usually severe (The case
fatality rate in humans is 5%, most severe in children). Prevalence of viral
infection is seasonally dependent, and incidences are usually observed in
summer and after heavy rainfalls (which are followed by an
increased mosquito population). In naturally infected hosts morbidity rate may
be as high as 5 % (in humans).
Virus is transmitted by a vector in a direct manner.
Virus is transmitted by mechanical inoculation; through an injection; not
transmitted by contact between hosts. Vector Transmission: Viral
transmission by vectors is frequent.
Virus is transmitted by arthropods, by
insects of the order
Diptera, family Culicidae,
Culicinae (culicine mosquitoes). Virus is transmitted in a persistent manner;
retained when the vector moults; circulates in hemolymph; does not require a
helper virus for vector transmission.
Non-Vector Transmission: The likelihood of viral transmission
by respiratory route (air-borne) is low; faecal-oral route (water and
food-borne) is low; direct contact is low; through sexual contact is low;
through parenteral transmission is low; through blood or blood products is low;
through congenital (germ line) transmission is rare; through transplacental
transmission is rare; through perinatal transmission is rare.
Experimental Hosts and Symptoms
Under
experimental conditions susceptibility to infection by virus is found in many
families.
Host:
Experimental host is susceptible to infection mice.
Experimentally infected hosts mainly show symptoms of similar neuro-virulence.
Diagnostic Hosts
For virus isolation
the most commonly used test animals are guinea pigs, mice; cell lines or tissue
cultures are chicken embryo, duck embryo, Vero cells. Virus has been propagated
in experimental animals, cell culture, and developing embryo.
Maintenance and Propagation Hosts
Most commonly used maintenance and propagation host species are suckling mice ,
Vero cells. Virus is propagated in embryonated eggs chicken, duck. Virus is
propagated in embryonated eggs by inoculating the amnion.
Assay Hosts
Host: Most
commonly used species for assaying the virus are suckling mice, Vero cells.
Pathology
Virus can be best detected in
nervous system; musculo-skeletal tissue, or brain tissue, or liver.
Histopathology: Histopathologic lesions are found in brain.
Virions are found in the cytoplasm. Primary histological changes include
inflammation, or necrosis.
Geographical distribution of the virus is probably
restricted. The virus spreads in North America and South and Central Americas.
The virus is known to occur in temperate regions, subtropical regions, and
tropical regions; viral host lives in the atmosphere. The viral host is found in
a pristine environment with no signs of human interference, or a undisturbed
environment yet with signs of human disturbance; an agricultural environment, or
an aquatic environment; a populated environment. The virus occurs in Mexico, the
United States of America, and Venezuela.
Epidemiological surveillance activities are overseen by Centers for Disease
Control and Prevention (CDC). A fact sheet on this virus is available from the
Centers for Disease Control and Prevention (CDC), National Center for Infectious
Diseases (NCID) (:
Arbovirus encephalitis)
(Emedicine: VEEV, and Medical
NBC online Information server:
VEEV).
List of Strains and
Isolates in the Species
00.073.0.01.026.02.001. VEEV, subtype I-C virus strain P676
00.073.0.01.026.03.001. VEEV, subtype I-D virus strain 3880
00.073.0.01.026.04.000.001. VEEV, subtype IE, isolate OAX142
00.073.0.01.026.04.000.002. VEEV, subtype IE, isolate OAX131
00.073.0.01.026.04.000.003. VEEV, subtype IE, isolate ISET-TAB91
00.073.0.01.026.04.000.004. VEEV, subtype IE, isolate ISET-CHI93
00.073.0.01.026.04.000.005. VEEV, subtype IE, isolate 63U16
00.073.0.01.026.00.004. VEEV, strain SH3
00.073.0.01.026.00.005. VEEV, strain Mena II
00.073.0.01.026.00.006. VEEV, TC-83 vaccine strain
00.073.0.01.026.00.007. VEEV, strain 3908
00.073.0.01.026.00.008. VEEV, strain 6119
00.073.0.01.026.00.009. VEEV, strain PMCHo5
00.073.0.01.026.00.010. VEEV, strain 80U76
00.073.0.01.026.00.011. VEEV, strain OAX142
00.073.0.01.026.00.012. VEEV, strain CPA201
00.073.0.01.026.00.013. VEEV, strain OAX131
00.073.0.01.026.00.014. VEEV, strain CPA152
00.073.0.01.026.00.015. VEEV, strain 52/73
00.073.0.01.026.00.016. VEEV, strain E541/73
00.073.0.01.026.00.017. VEEV, strain Ica
00.073.0.01.026.00.018. VEEV, strain E1/68
00.073.0.01.026.00.019. VEEV, strain V198
00.073.0.01.026.00.000.006. VEEV, isolate MAC87
00.073.0.01.026.00.000.007. VEEV, isolate MAC10
00.073.0.01.026.00.022. VEEV, Patent WO 9963098 virus Vaccine
00.073.0.01.026.00.023. VEEV, strain 80U76
00.073.0.01.026.00.024. VEEV, strain 73U157
00.073.0.01.026.00.025. VEEV, strain 77U214
00.073.0.01.026.00.026. VEEV, strain 71U384
00.073.0.01.026.00.027. VEEV, strain 71U338
00.073.0.01.026.00.028. VEEV, strain 67U217
00.073.0.01.026.00.029. VEEV, strain 67U201
00.073.0.01.026.00.030. VEEV, strain 63R20
00.073.0.01.026.00.031. VEEV, strain 2177B
00.073.0.01.026.00.032. VEEV, strain 67U208
00.073.0.01.026.00.033. VEEV, strain 83U434
00.073.0.01.026.00.034. VEEV, strain 243937
00.073.0.01.026.00.035. VEEV, strain 66457
00.073.0.01.026.00.036. VEEV, strain 66637
00.073.0.01.026.00.037. VEEV, strain E123/69
00.073.0.01.026.00.038. VEEV, strain Piura
00.073.0.01.026.00.039. VEEV, strain ZPC 738
00.073.0.01.026.00.040. VEEV, strain 71D-1252
00.073.0.01.026.00.041. VEEV, strain 75D143
00.073.0.01.026.00.042. VEEV, strain 71D1394
00.073.0.01.026.00.043. VEEV, strain 71D1392
00.073.0.01.026.00.044. VEEV, strain 71D1384
00.073.0.01.026.00.045. VEEV, strain 71D1317
00.073.0.01.026.00.046. VEEV, strain 71D1316
00.073.0.01.026.00.047. VEEV, strain 71D1315
00.073.0.01.026.00.048. VEEV, strain 71D1249
00.073.0.01.026.00.049. VEEV, strain 70U1134
00.073.0.01.026.00.050. VEEV, strain 93P1515
00.073.0.01.026.00.051. VEEV, strain 903843
00.073.0.01.026.00.052. VEEV, strain 903104
00.073.0.01.026.00.053. VEEV, strain F-322
00.073.0.01.026.00.054. VEEV, strain 240832
00.073.0.01.026.00.055. VEEV, strain P.Quintero
00.073.0.01.026.00.056. VEEV, strain 202330
00.073.0.01.026.00.057. VEEV, strain 8137
00.073.0.01.026.00.058. VEEV, strain 38851
00.073.0.01.026.00.059. VEEV, strain 52/73
00.073.0.01.026.00.060. VEEV, strain Panaquire
00.073.0.01.026.00.061. VEEV, strain 369673
00.073.0.01.026.00.062. VEEV, strain CoAn5384
00.073.0.01.026.00.063. VEEV, strain 69Z1
00.073.0.01.026.00.064. VEEV, strain Beck/Wycoff
00.073.0.01.026.00.065. VEEV, strain 71-180
00.073.0.01.026.00.066. VEEV, strain SH5
00.073.0.01.026.00.067. VEEV, strain DEI 5191
00.073.0.01.026.00.068. VEEV, strain Fe5-47et
00.073.0.01.026.00.069. VEEV, strain 59001
00.073.0.01.026.00.070. VEEV, strain CoAn 9004
00.073.0.01.026.00.071. VEEV, strain V209A
00.073.0.01.026.00.072. VEEV, strain IQT1724
00.073.0.01.026.00.073. VEEV, strain 76V2561
00.073.0.01.026.00.074. VEEV, strain 1385
00.073.0.01.026.00.075. VEEV, strain 34958
00.073.0.01.026.00.076. VEEV, strain 33571
00.073.0.01.026.00.077. VEEV, strain 23647
00.073.0.01.026.00.078. VEEV, strain BTR139707
00.073.0.01.026.00.079. VEEV, strain BT-2607
00.073.0.01.026.00.080. VEEV, strain 16927
00.073.0.01.026.00.081. VEEV, strain 16880
00.073.0.01.026.00.082. VEEV, strain 1327
00.073.0.01.026.00.083. VEEV, strain 335733
00.073.0.01.026.00.084. VEEV, strain 334250
00.073.0.01.026.00.085. VEEV, strain 309752
00.073.0.01.026.00.086. VEEV, strain 312714
00.073.0.01.026.00.087. VEEV, strain 310979
00.073.0.01.026.00.088. VEEV, strain 306425
00.073.0.01.026.00.089. VEEV, strain 307536
00.073.0.01.026.00.090. VEEV, strain 59145
00.073.0.01.026.00.091. VEEV, strain BeAn8
00.073.0.01.026.00.092. VEEV, strain V178
00.073.0.01.026.00.093. VEEV, strain 951327
00.073.0.01.026.00.094. VEEV, strain 951254
00.073.0.01.026.00.095. VEEV, strain 951289
00.073.0.01.026.00.096. VEEV, strain 951008
00.073.0.01.026.00.097. VEEV, strain 12563
00.073.0.01.026.00.098. VEEV, strain 10-1
00.073.0.01.026.00.099. VEEV, strain 6674
00.073.0.01.026.00.100. VEEV, strain ZGH734
00.073.0.01.026.00.101. VEEV, strain 9813
00.073.0.01.026.00.102. VEEV, strain 6803
00.073.0.01.026.00.103. VEEV, strain PHO 127
00.073.0.01.026.00.104. VEEV, strain V202
00.073.0.01.026.00.105. VEEV, strain 68U201
00.073.0.01.026.00.106. VEEV, strain 243797
00.073.0.01.026.00.107. VEEV, strain 125573
00.073.0.01.026.00.108. VEEV, strain 243884
00.073.0.01.026.00.109. VEEV, strain tc38
This description has been compiled
from data presented in the literature (Encyclopedia of Virology, Second Edition;
several special articles from the journal Virology).
Kinney
RM, Kiyotakar RT, Sneider JM, Trent DW (1992). Genetic evidence that epizootic
Venezuelan Equine Encephalitis (VEE) Viruses may have evolved from enzootic VEE
subtype I-D Virus. Virology 191, 569-580
Kinney RM, Johnson
BJB, Welch JB, Kiyotakar RT, Trent DW (1989). The full-length nucleotide
sequences of the virulent Trinidad Donkey strain of Venezuelan Equine
Encephalitis Virus and its attenuated Vaccine Derivative, strain
TC-83.Virology 170, 19-30.
The following generic references
are cited in the most recent ICTV Report
.
PubMed References. A description of this taxon can also
be found on the web at U.S. Centers for Disease Control and Prevention (CDC),
National Center for Infectious Diseases (NCID), United States Department of
Agriculture, and Emedicine.
Data have been submitted online to ICTVdB on 26-08-2002 by
Natalie Witte
Biosphere 2 Center
Columbia University
P.O. Box 689;
Oracle; A.Z. 85623, U.S.A.
email: ICTVdB Management.